Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination With Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer

NCT04648033 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT04648033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04648033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination With Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
Lead sponsor
University of Oxford
Phase
Phase 1
Overall status
Completed
Start date
December 7, 2020
Completion date
October 2, 2023
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced non-small cell lung cancer